CART Peptides as Modulators of Dopamine and Psychostimulants and Interactions with the Mesolimbic Dopaminergic System

George W Hubert, PhD, Douglas C Jones, PhD, Mark C Moffett, PhD, George Rogge, and Michael J Kuhar, PhD
Division of Neuroscience, The Yerkes National Primate Research Center of Emory University, 954 Gatewood Road, NE, Atlanta GA 30329, USA

Abstract

CART (cocaine- and amphetamine-regulated transcript) peptides (CART 55-102 and CART 62-102) are peptidergic neurotransmitters that are widely but specifically distributed throughout the brain, gut and other parts of the body. They are found in many brain regions associated with drug addiction including the nucleus accumbens, ventral tegmental area and ventral pallidum. Injections of CART 55-102 into the nucleus accumbens have no effect on basal locomotor activity. However, an injection of CART just before an i.p. injection of cocaine reduces the locomotor activating effects of cocaine. These and other data suggest that CART in the accumbens blunts the effects of cocaine. A hypothesis is that CART is homeostatic in the accumbens and tends to oppose large increases in dopamine signaling. These actions would therefore be able to regulate the effects of some abused drugs such as the psychostimulants.

CART: Discovery of an addiction-related peptide

In 1980, Speiss, et al.[1], obtained evidence that a CART peptide existed. In an extract from hypothalamus, they found a peptide with a new, previously unknown sequence that later was understood to be part of one of the CART peptides. Speiss, et al. [1], did not know the function or the exact localization of the peptide and referred to it as an unknown peptide. In 1995, Douglass, et al. [2], using differential display techniques, found an mRNA was upregulated after cocaine and amphetamine, but not after morphine, in the rat striatal region. This mRNA coded for a gene product that contained the peptide previously identified by Speiss, et al [1]. This lead to the naming of the peptide with the acronym, CART, which stands for cocaine and amphetamine regulated transcript [2]. Processing of proCART into active species, rat CART 55-102 and CART 62-102, has been described [3–5]. The amino acid sequence of rat CART peptide is shown in Figure 1. The human peptide is numbered differently since it is all in the spliced form (Figure 1).

Most of the general requirements needed to show that CART is a peptide neurotransmitter have been shown and summarized [1, 6–9]. CART peptide has been shown to be produced by neurons [1]. In addition, CART is packaged in large, dense-cored vesicles and present in nerve terminals that appose postsynaptic elements in the nucleus accumbens [7]. CART has
also been shown to effect changes in postsynaptic cells, specifically in the ERK pathway, which is affected by a number of G protein-coupled receptors [9, 10]. No specific clearance mechanism has been found for CART, though it is possible that synaptic CART levels are controlled by diffusion and peptidases. One major obstacle in investigating the functionality of CART is the lack of success in identifying a receptor devoted to CART neurotransmission.

Surprisingly, the work of Douglass, et al. [2], has not always been reproduced [11]. Nevertheless, there have been confirmatory reports using binge versus acute doses of cocaine [12, 13], and it is unclear why the increase in mRNA levels after psychostimulant injection is somewhat variable and not always found, although it may involve stress and a need for corticosterone [12]. More recent studies in animals have shown that CART mRNA levels increased after injection of methamphetamine or alcohol [14, 15]. Furthermore, in the post mortem human brain, CART mRNA levels are changed in the VTA and nucleus accumbens of cocaine overdose victims [16, 17]. Also a mutation in the CART gene is associated with alcoholism and not schizophrenia [18].

There is additional evidence that CART may be involved in addiction, but it is less direct. For example, over expression of CREB in the accumbens results in a reduction in rewarding effects of cocaine [19]. If CART peptide is inhibiting the effects of cocaine, then CREB over expression should increase CART in the accumbens. In fact, it has been shown that CART is regulated by CREB and that CREB over expression increases CART levels [20–22]. Thus, there is much evidence that does indeed suggest that CART is involved in modulating the action of psychostimulants and dopamine (DA).

**CART – DA interactions in the mesolimbic system**

Since a commonality of many addictive drugs is activation of the mesolimbic DA system, one would expect that CART and DA would interact, especially in light of CART’s interactions with cocaine. Electron microscopy shows that tyrosine hydroxylase-containing nerve terminals synapse on CART-containing neurons in the nucleus accumbens [6, 23]. Moreover, injection of D3 dopamine receptor agonists lowers levels of CART mRNA in the accumbens [24], and DA receptors are found on CART neurons [25, 26]. Injection of CART 55-102 into the ventricles causes an increased turnover of DA [27, 28]. CART-containing neurons in the nucleus accumbens core project to the substantia nigra zona compacta, while projections from the shell seem to be located more medially in the ventral tegmental area [29]. Injection of CART into the VTA, where cell bodies of the mesolimbic system are located, produces weak psychostimulant-like effects and causes an efflux of dopamine in the nucleus accumbens [30, 31]. However, a recent study found that injections of CART 55-102 into the VTA decreased locomotor counts following systemic administration of cocaine, especially at high doses of CART [32]. In summary, there are neurochemical data showing complex CART-DA interactions as pertains to the mesolimbic dopaminergic projection, and anatomical studies provide a physical basis to support this idea as well.

**Effects of CART peptide on the locomotor effects of cocaine and dopamine. in the nucleus accumbens**

It is well known that i.p. injection of cocaine into a rodent results in an increase in locomotor activity (LMA). When attempting to identify an effect of CART on cocaine, we had injected CART peptide into the nucleus accumbens and measured LMA. Injection of CART 55-102 alone into the nucleus accumbens had no effect, which was puzzling [33]. However, when CART was injected into the nucleus accumbens immediately after an i.p. injection of cocaine, it was found that the LMA effects of cocaine were blunted (Table 1). This effect of
CART has also been reported with respect to amphetamine-induced LMA [34]. So by itself, CART has no apparent effect when injected into the accumbens, but when combined with psychostimulants, it will blunt drug-stimulated LMA [33].

To explore this phenomenon further, dopamine was injected into the nucleus accumbens, and it produced the increases in LMA that have been observed previously using psychostimulants. When CART 55-102 and dopamine were co-administered in the same injection, the effects of dopamine were reduced [33]. Because cocaine acts through dopamine in producing LMA, the data suggest that CART tends to oppose the actions of dopamine and cocaine in the accumbens. Moreover, these findings suggest that the action of CART peptide is downstream of dopamine receptor activation. This could be due to many mechanisms, including a competition for intracellular signaling pathways [33].

A major reason why we chose to study the nucleus accumbens with injections of CART 55-102 is that the nucleus accumbens has a very high concentration of CART peptide [35]. CART neurons in the accumbens have recurrent collaterals and collateral innervations of CART neurons to both CART-containing and non CART-containing neurons. Electron microscopic studies show a substantial number of CART peptide-containing nerve terminals in the nucleus accumbens [7]. In addition, several areas that have CART peptide-containing cell bodies are known to project to the nucleus accumbens [36, 37]. Accordingly, because of the clear innervation of the nucleus accumbens by CART, it is concluded that the nucleus accumbens contains CART receptors, and that these receptors mediate the effects of CART peptides in the accumbens discussed above.

**CART and sensitization to psychomotor stimulants**

It is a well-documented characteristic of psychomotor stimulants to produce a sensitization of locomotor activity with repeated doses. In studies in CART knockout mice, repeated doses of amphetamine produce a much smaller and delayed locomotor sensitization than in controls [38]. This is in direct contrast to a separate study, using different CART knockout mice, that found no change in the sensitization to cocaine in CART knockouts [39]. Moreover, repeated injection of CART 55-102 into the VTA of rats, an area critical to the development of sensitization to amphetamine, is not sufficient to induce sensitization to cocaine or amphetamine [30]. These data imply that CART in and of itself is not sufficient to produce psychomotor stimulant sensitization, but that increased levels of dopamine are necessary.

**Studies using CART knockout mice**

Currently, there are two separate strains of knockout mice available for research. One that deletes exons I and II [40] and one that deletes all three exons [41]. For review, see Moffett et al. [42]. CART knockout mice typically feed more than wild type, and increased body weight is especially evident when the mice are given a high caloric diet [40]. In addition, the knockout mice generated by Wierup et al. [41], also show increased weight as well as impaired pancreatic function, which may be the cause of altered body weight.

Various studies disagree on the effects of the absence of CART on the function of systems affected by psychomotor stimulants. Couceyro et al. [38], using the mice generated by Wierup et al. [41] reports that locomotor activity was decreased after cocaine and that vertical and stereotypic activity were decreased after amphetamine in the CART knockout group. In addition, responding for intravenous cocaine and total cocaine consumption were reduced in CART knockouts. CART knockout mice also did not show any sensitization to the effects of amphetamine. The same mice, however showed no inhibition of open field activity and sucrose preference, indicating that the elimination of the CART gene did not
effect locomotor ability or taste preference [38]. In contrast, separate studies using the different strain of CART knockout mice did not detect a difference in cocaine-induced locomotor activity, cocaine self-administration or sensitization to the behavioral effects of cocaine [39, 42]. Additional studies will be needed to reliably ascertain effects of knocking out CART.

A search for the CART receptor

When CART was first identified as an important brain peptide in the late 1990s, many laboratories prepared radiolabeled CART peptide and attempted to find the receptors for CART in binding studies. Surprisingly, these studies all failed for unknown reasons. It seemed possible that the CART receptor had a low affinity for radiolabeled CART peptide, and therefore had a rapid rate of unbinding which precluded the identification of specific binding in a binding approach. Alternatively, the receptor number could be very low – below the limits of detection, or, the number of non-specific binding sites could be overwhelmingly high. In any case, until a couple of years ago, the CART receptor was largely uncharacterized.

After taking a new approach, that is exploring cell lines for CART-induced signaling events, it was found that application of CART55-102 to AtT20 cells resulted in an increase in P-ERK-1 and P-ERK-2 [9]. Shortly thereafter, Vicentic et al. [10] identified specific binding in the same cell line under the same conditions (Figure 2). Thus, CART-specific receptor binding has been identified. Moreover, the binding of the agonist CART peptide was reduced in the presence of excess GTP analogue, but not in the presence of excess ATP analogue, indicating that the CART receptor being studied in the AtT20 cells was a G protein-coupled receptor. Furthermore, pertussis toxin inhibited CART signaling indicating that the GPCR was coupled with a Gi or a Go protein [9]. More recently, another laboratory found CART receptor binding in differentiated PC12 cells [43]. These breakthroughs are likely to lead to additional studies on CART receptor binding and to the identification of the gene or genes for the CART receptor or receptors. This will not only lead to a new understanding of CART systems in brain and other tissues, but will also facilitate drug screening for potential CART agonists and antagonists.

CART in other processes

One of the most interesting things about CART peptides is that they appear to be involved in a number of physiological functions including feeding and body weight [36, 44]. One of the first experiments carried out after the discovery of CART were injections of CART peptide into the ventricles of rodents, which resulted in an inhibition of feeding, while an injection of antibodies resulted in an increase in feeding ([45–47]. Human genetic studies also support this hypothesis. A missense mutation has been associated with early onset obesity [48] and another mutation associates with increased weight [49] The issue of CART and body weight has been critically reviewed [44].

Changes in CART levels have been associated with stress [50, 51]), and CART 55-102 has antinociceptive effects [52–54]. Evidence is increasing for a role for CART in endocrine regulation [27, 55–57]. Also CART has neurotrophic [58, 59] as well as vasoconstrictor properties [60–62].

Hypothesis: CART is a homeostatic regulator in the nucleus accumbens

A consideration of available data suggests that CART 55-102 (or CART 62-102) is a peptide neurotransmitter that functions as a homeostatic regulator in the nucleus accumbens. In other words, as dopamine signaling in the nucleus accumbens becomes great, CART peptide is
released and tends to oppose these actions of dopamine (Figure 3). It is not surprising that such a regulatory system(s) could exist in the nucleus accumbens. The major evidence for this are the LMA studies noted above (Table 1) and some recent studies appearing in an abstract [63] which suggest that accumbal CART peptide reduces the rewarding effects of cocaine by inhibiting cocaine self-administration patterns.

There are, however, some difficulties with this theory. It is difficult to fully understand the action of a substance when the only approach available is to increase levels of the transmitter in question. Studies of CART knockout mice in the context of drug abuse have been conducted, but these studies have produced conflicting results [42]. Other ways of manipulating CART systems will have to be developed to fully explore the functions of CART peptides.

Acknowledgments

The authors acknowledge the support if grants RR00165, DA10732, DA015040, DA00418, and individual NRSAs: DA021056, 5F31DA0219 and DA20312.

Abbreviations

CART  cocaine- and amphetamine-regulated transcript

References


Figure 1.
Sequence of the ProCART peptide. In the rat, there are 2 splice variants; amino acids 27–39 (in italics) are spliced out from the long form of 102 amino acids to give the short form of 89 amino acids. The fragments of the long form that have been reliably shown to be active are CART 55-102 and CART 61-102 (in the short form the numbers are CART 42-89 and CART 49-89). In humans, the splicing is complete and only the short 89 amino acid form exists, with some changes in amino acids. Position 42 which is isoleucine in the rat is a valine in the human. Underlined pairs of basic amino acids indicate sites of processing by prohormone convertases.
Figure 2.
Identification of specific saturable binding of radiolabeled CARTpeptide to AtT20 cells. The Kd is subnanomolar, and the binding is specific for CART 55-12 and CART 62-102; no other tested peptide or substance inhibited the binding. Reproduced from Vicentic et al., 2005.
Figure 3.
A hypothesis in schematic form about a function of CART peptide in the Nucleus accumbens (Acc). Its action is to oppose the changes induced by cocaine. When CART is given alone into the Acc, it has no effect, but when coadministered with DA or cocaine, it tends to block the locomotor effects of those compounds. While the cellular mechanisms of these CART-DA receptor interactions have not yet been clarified, perhaps candidates would be heterologous desensitization and/or interfering downstream signaling pathways from CART and DA receptors.
Table 1

Effect of CART on Cocaine-induced LMA

<table>
<thead>
<tr>
<th>Cocaine Dose (mg/kg)</th>
<th>Cocaine LMA (cm)</th>
<th>Coc + CART LMA (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>26,000</td>
<td>12,000</td>
</tr>
<tr>
<td>30</td>
<td>33,000</td>
<td>16,000</td>
</tr>
</tbody>
</table>

CART 55-102 peptide (2.5 ug each side into the nucleus accumbens) blunts the LMA induced by cocaine. CART 1-27, and inactive CART peptide, had no effect. LMA – locomotor activity. Data from Jaworski et al 2003.